GGN[GuiltyGearNullpo]

ギルティギア関連情報サイト
ギルティギアぬるぽ

 
投稿者
メール

 
コメント
URL
コメントは新しいものから表示されます。
コメント本文中とURL欄にURLを記入すると、自動的にリンクされます。
投稿者:xkqaetqunk
Hello! Good Site! Thanks you! aseudgzmeq

http://xkqaetqunk.com
投稿者:pfgrrrawff
Add UV radiation from the sun, and the magnitude of sorting out what is truly carcinogenic becomes evident. Aging is a major cause of cancer, associated not just with chemicals, but a normal process called telomere shortening. So, except for high exposure workers, it is completely unfounded to claim that there exists a chemically driven cancer epidemic. Accusing cancer researchers of choosing not to address prevention shows a lack of understanding of the biology of cancer. To infer that the interest in therapeutics derives from the fact that cancer treatment has somehow become an industry is to be misinformed. Despite ads suggesting that drug companies...<a href='http://bestnews-4u.com/news/3529'>http://bestnews-4u.com/</a>
投稿者:zdilsdylrt
Another big drug maker, Pfizer, for example, was harshly criticized in 2001 for reporting that its painkiller Celebrex caused fewer ulcers than older drugs after six months of use. Pfizer痴 study had originally been designed but failed to show that Celebrex caused fewer ulcers after a full year of use. Yesterday, Merck and Schering said they did not yet know the results of the trial. They said they were changing the endpoint only because they want to be able to analyze the data more quickly. A panel of outside scientists recommended the change last Friday, said Lee Davies, a spokesman for Schering. Mr. Davies declined to disclose the members of the panel. Dr. Howard Weintraub, the clinical director of the New York University center for the prevention of cardiovascular disease, said cardiologists were especially concerned about the trial痴 results because Zetia works...<a href='http://coolnews-4u.com/news/3816'>http://coolnews-4u.com/</a>
投稿者:hucfyhtyye
Hello! Good Site! Thanks you! oubzwfluerbrrc

http://hucfyhtyye.com
Copyright (C) GMO Tea Cup Communication, Inc. All Rights Reserved.